---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-23-000010"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2023-01-03T23:59:59+00:00"
generated_at: "2026-06-20T20:50:51.222255+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Chemomab CM-101 Phase 2a NASH trial meets safety endpoint; shows positive fibrosis biomarker activity

## Summary
- Trial met primary endpoint: safety and tolerability; no significant injection site reactions, no anti-drug antibodies.
- 23 NASH patients (F1c-F3) received 8 SC doses of 5 mg/kg or placebo over 16 weeks.
- CM-101 showed greater improvements vs placebo in fibrosis biomarkers ProC-3, ProC-4, ProC-18, TIMP-1, ELF.
- Nearly 60% of CM-101 patients responded in ≥3 fibrosis biomarkers at week 20 vs 0% placebo.
- Higher baseline CCL24 correlated with greater biomarker reductions; FibroScan liver stiffness improved vs placebo.

## SEC filing metadata
- accession: 0001178913-23-000010
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2023-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891323000010/0001178913-23-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891323000010/zk2328943.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-23-000010
- JSON: https://secwatch.observer/filing/0001178913-23-000010.json
- Plain text: https://secwatch.observer/filing/0001178913-23-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.